Neurogene Inc. filings document a clinical-stage biotechnology issuer developing genetic medicines for rare neurological diseases. Recent 8-K reports furnish operating results, corporate presentations, clinical and regulatory updates for NGN-401 in Rett syndrome, and material-event disclosures tied to board appointments and executive compensation arrangements.
The company's proxy materials cover director elections, board committee matters, executive compensation, equity awards, pay-versus-performance disclosure, and stockholder voting procedures. Together, the filings describe Neurogene's governance framework, common-stock compensation practices, and formal disclosures around its gene-therapy pipeline and financial condition.
Neurogene Inc. reported that Chief Scientific Officer Cobb Stuart acquired 16,500 shares of common stock in the form of restricted stock units. These units were granted at no cash cost and will vest in three equal annual installments starting on February 20, 2027, contingent on continued service.
After this grant, Stuart holds 37,294 restricted stock units in total, reflecting multiple prior awards. According to the footnotes, these earlier grants vest annually from March 13, 2025 through March 13, 2027 and from March 26, 2026 through March 26, 2028, with the new grant vesting through February 20, 2029.
Neurogene Inc. reported that Chief Medical Officer Jordan Julie acquired equity awards on February 20, 2026. The awards include a stock option for 29,600 shares of common stock and 4,900 restricted stock units, both subject to multi‑year vesting tied to continued service.
Neurogene Inc. reported that President and CFO Christine Mikail Cvijic received new equity awards. On February 20, 2026 she was granted a stock option for 131,900 shares of common stock at an exercise price of $0.00 per share. One quarter of this option vests on the first anniversary of the grant, with the remaining three quarters vesting in equal monthly installments through the fourth anniversary, conditioned on continued service. She also received 22,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date, also subject to continued service. Following these awards, her directly held common stock position is 114,643 shares, including previously granted restricted stock units and 24,000 shares held jointly with her spouse.
Neurogene Inc. reported that Chief Executive Officer and director Rachel McMinn acquired new equity awards. On February 20, 2026, she received a stock option covering 155,100 shares of common stock at an exercise price of $0.00 per share, vesting over four years as described in the filing. She also received 25,900 restricted stock units, vesting in three equal annual installments starting on the first anniversary of the grant date, contingent on continued service. After the reported common stock award, McMinn beneficially owned 1,347,659 shares of common stock directly, including previously granted restricted stock units, and the filing notes an earlier administrative understatement of her reported holdings that is now corrected.
PALEKAR ROHAN reported acquisition or exercise transactions in this Form 4 filing.
Neurogene Inc. director Rohan Palekar received a grant of 12,050 non-qualified stock options on February 20, 2026. These options give him the right to buy Neurogene shares if and when they vest.
The award vests in equal monthly installments over one year, with 1/12 of the options vesting each month starting March 20, 2026 and becoming fully vested by February 20, 2027, as long as he continues providing service to the company on each vesting date.
Neurogene Inc. director Robert Baffi received a grant of 12,050 non-qualified stock options on February 20, 2026. The options have a $0.00 exercise price and vest in equal 1/12 installments each month from March 20, 2026 through February 20, 2027, contingent on continued service.
Neurogene Inc. director Sarah B. Noonberg received a grant of non-qualified stock options for 12,050 shares at an exercise price of $0.00 per share. The option vests in equal monthly installments of 1/12 from March 20, 2026 until fully vested on February 20, 2027, conditioned on continued service.
Freedland Cory S. reported acquisition or exercise transactions in this Form 4 filing.
Neurogene Inc. director Cory S. Freedland reported receiving a grant of 12,050 non-qualified stock options. The options were awarded at a disclosed price of $0.0000 per option and are held directly.
The option grant vests in equal 1/12 monthly installments starting on March 20, 2026, and will be fully vested on February 20, 2027, as long as Freedland continues providing service to Neurogene on each vesting date.
Neurogene Inc. director Woods Keith reported receiving a grant of non-qualified stock options covering 12,050 shares of Neurogene common stock. This is classified as an acquisition of derivative securities as a grant or award, rather than an open-market purchase or sale.
According to the disclosure, the option vests in equal monthly installments of 1/12 of the total shares beginning on March 20, 2026, and will be fully vested by February 20, 2027. Vesting is conditioned on Keith continuing to provide services to Neurogene on each vesting date, meaning the award is tied to ongoing service over this roughly one-year period.
Neurogene Inc. has a significant institutional holder disclosing a 9.9% stake in its common stock. Redmile Group, LLC and its principal, Jeremy C. Green, report beneficial ownership of 1,557,179 shares, equal to 9.9% of the company’s common stock, including shares that could be issued from pre-funded warrants.
Those warrants are subject to a 9.99% Beneficial Ownership Limitation, which caps how many shares can be issued so their ownership does not exceed that threshold. An affiliated fund, Redmile Biopharma Investments I, L.P., reports beneficial ownership of 749,610 shares, or 4.8% of the class. The reporting persons certify the securities are not held to change or influence control of Neurogene.